Clinical Trial Update: A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders [Phase 2]

View source ↗

Summary

A Phase IIb trial of nabiximols for spasticity in neuromyelitis optica spectrum disorders has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Nabiximols (tetrahydrocannabinol and cannabidiol oromucosal spray)

Snippet

Sponsor: Michael, Levy M.D.,Ph.D. | Conditions: NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Status: WITHDRAWN